Innovative Technology Saranas offers the only FDA-approved early bleed detection system embedded within vascular access sheaths, providing a unique value proposition for hospitals performing complex endovascular procedures and those seeking advanced patient monitoring solutions.

Growing Clinical Adoption With over 1,200 patients treated using the Early Bird Bleed Monitoring System and ongoing clinical trials like SAFE-MCS, there are clear opportunities to expand within high-risk cardiovascular intervention centers aiming to improve patient safety and reduce complications.

Strategic Funding Milestones Recent successful Series B funding of $12.8 million highlights investor confidence and potential for scaling sales efforts, especially targeting hospital systems and medical device distributors focused on innovative vascular technologies.

Market Expansion Potential Saranas is positioned to capitalize on the growing demand for minimally invasive and safety-enhancing devices in interventional cardiology, opening doors to collaborations with large healthcare providers and corporate partners committed to tech-driven procedural improvements.

Leadership & Growth New appointment of a seasoned CEO and continuous product development, including launching clinical trials, indicate the company's strategic focus on strengthening market presence and fostering relationships with key decision-makers in cardiovascular care.